Findings may help inform beneficial infusion modifications.
ONCOLOGY
Fully funded by 
Content independently selected
-
NHL: study identifies 2 risk factors for rituximab infusion reactions -
R/R DLBCL: ibrutinib, lenalidomide, rituximab regimen promising in non-GCB disease Median duration of response not reached in patients with complete response.
-
Advanced Hodgkin lymphoma: 5-year data show limited PET2 predictive power 1 in 4 PET2-negative patients experienced progression at 5 years.
-
Secondary CNS lymphoma: tisagenlecleucel active with low neurotoxicity risk Largest cohort of its kind in this setting.
-
Follicular lymphoma: rituximab maintenance yields sustained PFS benefit at 9 years Data from the phase 3 PRIMA trial.
-
FDA prompts recall of Allergan's textured breast implants tied to anaplastic large-cell lymphoma Allergan issues recall of BIOCELL textured implants and tissue expanders.
-
R/R HL: GVDex may be a cheaper, less toxic alternative to GVDoxil More than 6 in 10 1L salvage patients achieved CR.
-
Mantle cell lymphoma: charting disease course across multiple treatment lines Early treatment failure linked to inferior PFS, OS.
-
Molecular characterization of pediatric mixed phenotype acute leukemia Rare disease shows no distinct molecular characteristics.
-
Lymphoma survivors: study highlights value of follow-up for late adverse events Knowledge deficits identified in certain patient types.
-
Lenalidomide+obinutuzumab active in pretreated follicular lymphoma Phase 2 GALEN shows comparable response in patients with early relapse.
-
Hematological malignancies: malnutrition a significant threat to survival 1 in 4 patients met criteria for malnourishment.
-
Primary CNS lymphoma: ibrutinib achieves favorable disease control in phase 2 Response observed in all CNS compartments.
-
Depression tied to poor survival in blood cancers Effect persisted with recovery from depression.